Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EPS (Basic) (2022 - 2025)

Entrada Therapeutics has reported EPS (Basic) over the past 4 years, most recently at -$0.94 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.94 for Q4 2025, down 3033.33% from a year ago — trailing twelve months through Dec 2025 was -$3.46 (down 279.27% YoY), and the annual figure for FY2025 was -$3.47, down 297.16%.
  • EPS (Basic) for Q4 2025 was -$0.94 at Entrada Therapeutics, up from -$1.06 in the prior quarter.
  • Over the last five years, EPS (Basic) for TRDA hit a ceiling of $1.61 in Q2 2024 and a floor of -$1.06 in Q3 2025.
  • Median EPS (Basic) over the past 4 years was -$0.55 (2025), compared with a mean of -$0.3.
  • Biggest five-year swings in EPS (Basic): surged 433.33% in 2024 and later tumbled 3033.33% in 2025.
  • Entrada Therapeutics' EPS (Basic) stood at -$0.78 in 2022, then skyrocketed by 62.82% to -$0.29 in 2023, then surged by 89.66% to -$0.03 in 2024, then tumbled by 3033.33% to -$0.94 in 2025.
  • The last three reported values for EPS (Basic) were -$0.94 (Q4 2025), -$1.06 (Q3 2025), and -$1.04 (Q2 2025) per Business Quant data.